Tanya Bronzell-Wynder
Family · Camden, NJNPI 1013913797
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (53.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. Astellas Pharma US Inc accounts for 88.1% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $9,623 and has fallen 94.5% since, to $534 in 2025. Among family clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 92 payments — averaging $158.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$13K
- AstraZeneca$988
- Amgen$135
- Mylan Specialty L.p.$85
- Advanced Respiratory, Inc$77
- Lilly USA, LLC$73
- plus $382 from 12 others
What the payments were for
- Speaking & faculty fees$7,83054%
- Travel & lodging$3,82326%
- Food & beverage$2,59518%
- Education$3412%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 37 | $12,849 |
| AstraZeneca | 13 | $988 |
| Amgen | 6 | $135 |
| Mylan Specialty L.p. | 5 | $85 |
| Advanced Respiratory, Inc | 4 | $77 |
| Lilly USA, LLC | 5 | $73 |
| GSK | 4 | $63 |
| Boston Scientific | 2 | $52 |
| Pfizer | 3 | $49 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Paratek Pharmaceuticals, Inc. | 2 | $33 |
| Johnson & Johnson | 1 | $29 |
| Electromed, Inc. | 2 | $28 |
| Sunovion Pharmaceuticals Inc. | 2 | $25 |
| Insmed, Inc. | 1 | $23 |
| Mallinckrodt Hospital Products Inc. | 1 | $18 |
| Boehringer Ingelheim | 1 | $15 |
| Viatris Specialty LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,589 in reported general payments places this provider in the 95th percentile of 2,692 family providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 176 | $109,187 |
| PrevymisLetermovir | 13 | $91,024 |
| Atovaquone | 164 | $88,253 |
| Valganciclovir Hcl | 186 | $45,618 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $40,997 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 46 | $30,474 |
| JardianceEmpagliflozin | 29 | $25,561 |
| TrulicityDulaglutide | 19 | $20,128 |
| LinzessLinaclotide | 33 | $16,679 |
| Efavirenz-Lamivu-Tenofov DisopEfavirenz/Lamivu/Tenofov Disop | 11 | $14,162 |
| Sirolimus | 42 | $13,818 |
| Breo ElliptaFluticasone/Vilanterol | 39 | $12,834 |
| Voriconazole | 44 | $9,966 |
| Tacrolimus | 104 | $9,611 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 16 | $8,354 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis, Premarin | $49 | $110,643187 claims |
| GSKAnoro Ellipta, Trelegy Ellipta, Breo Ellipta | $63 | $84,306156 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $15 | $31,87442 claims |
| Lilly USA, LLCTrulicity | $73 | $20,12819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,692 family providers in New Jersey.
Other family in Camden
- Jennifer DemaioMorristown$412K
- Kara TrlicaCranbury$186K
- Nicole BauerParamus$161K
- China BattistaWall Township$142K
- Nancy EisenbergerVoorhees$82K
- Jennifer AbitabiloGlen Ridge$54K
- Megan FiloramoMorristown$53K
- Shawn DenningToms River$29K
- Kimberly ClementeEatontown$25K
- Toni Michelle SeibertColumbus$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.